Flowserve (NYSE: FLS) reported earnings on April 30. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Flowserve met expectations on revenue and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share dropped slightly.

Gross margin dropped, operating margin expanded, and net margin shrank.

Revenue details
Flowserve reported revenue of $1.07 billion. The 11 analysts polled by S&P Capital IQ hoped for revenue of $1.07 billion on the same basis. GAAP reported sales were 7.8% higher than the prior-year quarter's $997.2 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $1.69. The 10 earnings estimates compiled by S&P Capital IQ predicted $1.62 per share. GAAP EPS of $1.69 for Q1 were 1.7% lower than the prior-year quarter's $1.72 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 33.4%, 150 basis points worse than the prior-year quarter. Operating margin was 12.8%, 30 basis points better than the prior-year quarter. Net margin was 8.7%, 100 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $1.18 billion. On the bottom line, the average EPS estimate is $2.01.

Next year's average estimate for revenue is $4.80 billion. The average EPS estimate is $8.66.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 842 members out of 862 rating the stock outperform, and 20 members rating it underperform. Among 195 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 193 give Flowserve a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Flowserve is buy, with an average price target of $140.80.